Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 5 versus DANZITEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 5 versus DANZITEN.
ANDROID 5 vs DANZITEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; stimulates protein synthesis and growth of androgen-sensitive tissues.
Selective inhibitor of nuclear export (SINE) that binds to and inhibits exportin 1 (XPO1), preventing export of tumor suppressor proteins and growth regulators from the nucleus, leading to cell cycle arrest and apoptosis.
2.5-10 mg orally once daily in the morning for androgen replacement therapy in adult males.
1.5 mg orally once daily, increased at 2-week intervals to 3 mg once daily, then 5 mg once daily based on tolerability and efficacy.
None Documented
None Documented
Terminal elimination half-life is 3.5–5.5 hours; clinical effects may persist for several days due to active metabolites.
Approximately 10-12 hours in adults; may be prolonged in hepatic impairment (up to 20 hours).
Primarily renal: ~90% as glucuronide and sulfate conjugates, 6% as unchanged drug; ~5% fecal via bile.
Primarily hepatic metabolism followed by renal excretion of metabolites; <5% excreted unchanged in urine.
Category C
Category C
Androgen
Androgen/Antigonadotropin